WEST PHARMACEUTICAL SERVICES INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.1B | $2.9B | $2.9B | $2.9B | $2.8B |
| Gross profit | $1.1B | $998.5M | $1.1B | $1.1B | $1.2B |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M |
| Cost of revenue | $2.0B | $1.9B | $1.8B | $1.8B | $1.7B |
| Cash from operations | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M |
| Capital expenditure | $285.9M | $377.0M | $362.0M | $284.6M | $253.4M |
| Free cash flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M |
| Share repurchases | $134.0M | $560.9M | $438.3M | $202.8M | $137.1M |
| Impairments | $11.7M | $7.3M | $9.6M | $6.2M | $5.6M |
| Total assets | $4.3B | $3.6B | $3.8B | $3.6B | $3.3B |
| Total liabilities | $1.1B | $961.1M | $948.5M | $931.9M | $978.4M |
| Total debt | $203.0M | $203.0M | $207.0M | $209.2M | $253.5M |
Shares outstanding 70.6M · Free float 92.8%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.